Menu

CME Corner

This activity has expired. CME/CE credit is no longer available and the following content may not be available or may not be up-to-date. For a list of current activities that offer CME/CE credit, click here.

Program Detail

Release Date: April-30-08
Credit Expiration Date: April-30-10

Faculty

Michael S. Blaiss, MD
Clinical Professor of Pediatrics & Medicine
University of Tennessee Health Services Center
Memphis, Tennessee

Eli O. Meltzer, MD
Clinical Professor of Pediatrics
University of California at San Diego
San Diego, California

Credit Hours

1.0 Physician CME

Medium

i-Newsletter

Program Description

CREDIT IS AVAILABLE FOR PHYSICIANS, ONLY.

Conjunctivitis and asthma are two of the more common non-nasal comorbidities associated with rhinitis. Whether experienced as mild or severe, these comorbidities can seriously affect quality of life and productivity for patients and they make management more complicated for clinicians.

Program Developer/Facilitator


.

Target Audience

This educational activity is designed to meet the needs of physicians specializing in allergy and immunology, ophthalmologists, and physicians in family medicine, pediatrics, and internal medicine.

Learning Objectives

Upon completion of this educational activity, the participant should be able to:

  1. Describe the comorbidities of conjunctivitis and asthma associated with rhinitis and how they affect quality of life for patients and treatment decisions by clinicians.
  2. Evaluate effective pharmacologic strategies for managing rhinitis-conjunctivitis and rhinitis-asthma.
  3. Summarize the role of intranasal steroids, antihistamines, and other agents when treating patients with complex symptoms associated with rhinitis.

Disclosures

It is the policy of AKH Inc. to ensure independence, balance, objectivity, scientific rigor, and integrity in all of its continuing education activities. The faculty must disclose to the participants any significant relationships with commercial interests whose products or devices may be mentioned in the activity or with the commercial supporter of this continuing education activity. Identified conflict of interest is resolved by AKH prior to accreditation of the activity. AKH planners and reviewers have no relevant financial relationships to disclose.

This educational activity may contain discussion of published and/or investigational uses of pharmacologic agents. Some uses may not have been approved by the FDA. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Dr. Blaiss discloses speakers' bureau service and advisory committee participation for Alcon, AstraZeneca, GlaxoSmithKline, Inspire, Merck, sanofi-aventis, Schering-Plough, and Teva. He previously owned stock in Schering-Plough.

Dr. Meltzer discloses speakers' bureau service for Alcon, Altana, AstraZeneca, Genentech, Genesis, GlaxoSmithKline, MedPointe, Merck, Pfizer, sanofi-aventis, Schering-Plough, and Verus. He has also served as a consultant for Abbott, Adelphi, Alcon, Allux, Amgen, AstraZeneca, Capnia, Critical Therapeutics, Dey, Evolutec, Genentech, GlaxoSmithKline, Greer, Inspire, KOS, MedPointe, Merck, Novartis, Nycomed (Altana), Pfizer, Rigel, sanofi-aventis, Schering-Plough, Shionogi, Verus, and Wyeth. He discloses receiving grant/research support from Alcon, Allux, AstraZeneca, Boehringer Ingelheim, Capnia, Clay-Park, Critical Therapeutics, Genentech, GlaxoSmithKline, Hoffmann-LaRoche, KOS, Medicinova, MedPointe, Merck, Novartis, Nycomed (Altana), Pharmaxis, Rigel, sanofi-aventis, Schering-Plough, Teva, and Wyeth.

Credit Statements

This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of AKH, Inc. and Medical Communications Media, Incorporated. AKH, Inc. is accredited by the ACCME to provide continuing medical education for physicians.

AKH, Inc. designates this educational activity for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Commercial Support Statements

This activity is supported by an educational grant from Schering-Plough.

Certificate Fee

$0.00

Disclaimer

©2008 Medical Communications Media, Inc. All rights reserved. None of the contents may be reproduced in any form without prior written permission from the publisher. The opinions expressed in this publication are those of the presenters and do not necessarily reflect the opinions or recommendations of their affiliated institutions, the publisher, AKH Inc., WSAAI, or Schering-Plough Corporation. Any medications, diagnostic procedures, or treatments discussed by the program presenters should not be used by clinicians or other healthcare professionals without first evaluating their patients’ conditions, considering possible contraindications or risks, reviewing any applicable manufacturer’s product information, and comparing any therapeutic approach with the recommendations of other authorities.

By clicking START PROGRAM I acknowledge that I have read the CME/CE information above.

Main Menu
EDITOR'S PICKS